Core Viewpoint - The stock market presents compelling opportunities as the US economy shows resilience, the AI boom continues, and equity rallies broaden beyond a few leading stocks, creating favorable conditions for stock selection heading into 2026 [1] Group 1: Zacks Rank and Stock Selection - The Zacks Rank is highlighted as an effective investment tool with a strong track record of identifying emerging leaders before they gain widespread recognition [2] - Three stocks are identified as top picks: Pagaya Technologies Ltd. (PGY), Eli Lilly (LLY), and Weatherford International (WFRD), all carrying a top Zacks Rank and backed by strong growth expectations and attractive valuations [3] Group 2: Eli Lilly (LLY) - Eli Lilly has shown exceptional performance due to the adoption of GLP-1 weight-loss therapies, experiencing a powerful stock advance towards the end of 2025 after a temporary pause [5][6] - The stock is currently rated Zacks Rank 1 (Strong Buy) with earnings estimates revised upward, trading at 32.2x forward earnings, and projected EPS growth of 41.4% annually over the next three to five years [6] - Technical analysis indicates a bullish setup, with a recent breakout above resistance levels suggesting potential for further gains [7] Group 3: Pagaya Technologies Ltd. (PGY) - Pagaya Technologies is positioned in the "buy now, pay later" (BNPL) space, previously highlighted for its strong growth projections and attractive valuation, with shares having more than tripled before a significant pullback [9][10] - The stock has returned to a Zacks Rank 1 (Strong Buy), trading at 6.5x forward earnings, with sales expected to grow by 28.4% this year and 19.2% next year, alongside a projected earnings growth of 274% [10] - Recent technical movements indicate a potential pivot point for renewed buying interest, suggesting favorable conditions for investors [11] Group 4: Weatherford International (WFRD) - Weatherford International's shares have risen sharply amid geopolitical developments affecting global energy markets, particularly following military actions in Venezuela [13] - The stock has maintained a top Zacks Rank and has shown signs of renewed leadership in the energy sector prior to recent events [14] - Technical analysis shows a decisive breakout from a bull flag pattern, reinforcing a bullish outlook for Weatherford and the broader energy sector [15] Group 5: Investment Considerations - Each of the highlighted stocks offers unique investment opportunities: Eli Lilly as a structural growth leader, Pagaya as a high-upside growth story, and Weatherford as a play on a resurgent energy cycle [16]

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer's Pharmaceuticals Division, will present updates on the company's pharmaceutical growth strategy and pipeline advancements across its portfolio. The presentation will take place on Tuesday, January 13, 2026, from 11:15 to 11:55 PST. Investors, analysts. ...

The Tel Aviv Stock Exchange rose today. The Tel Aviv 35 Index rose 1.16% to 3,738.33 points - a new record, the Tel Aviv 125 Index rose 1.64% to 3,794.16 points; and the BlueTech Global Index rose 2.30% to 658.99 points. The All Bond corporate bond index rose 0.54% to 423.54 points. Turnover totalled NIS 5.91 billion in equities and NIS 6.84 billion in bonds. On the foreign exchange market, the representative shekel-dollar rate was set 0.723% lower from Friday, at NIS 3.203/$, and the representative sheke ...

Novo Nordisk A/S (NYSE:NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.Novo Nordisk stock is charging ahead with explosive momentum. What’s fueling NVO momentum?Wegovy pill showed an average weight loss of about 17% (16.6%) when used along with a reduced-calorie diet and exercise, and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.When looking at the efficacy regardless of whether all patients stayed on treatment, an average weight loss ...

Key Points The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the developmental work this pharma icon has going on. At the very least, the drug stock’s current dividend payment is well protected. 10 stocks we like better than Pfizer › The average blue chip dividend stock's current yield is somewhere in the ballpark of 3% to 4%. Therefore, to see one paying out nearly 7% of its value is as suspicious as it is impressive. When the ...

Incyte Corporation (NASDAQ:INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).The trial evaluated tafasitamab and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) compared to R-CHOP alone.The trial met its primary endpoint of progression-free survival (PFS). The trial also met its key seco ...

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition ageBrigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms Allschwil, Switzerland – January 5, 2026Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insight ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Key Takeaways IRWD stock jumped 26.7% on Jan. 2 after the company issued upbeat revenue guidance for 2026.Ironwood expects $450-$475M in 2026 revenues and more than $300M in adjusted EBITDA.IRWD to start a phase III study on apraglutide in 1H26 after aligning with the FDA on study design.Shares of Ironwood Pharmaceuticals (IRWD) were up 26.7% on Jan. 2 after the company announced upbeat revenue guidance for 2026. The company maintained its revenue guidance for full-year 2025, which it had provided in Novemb ...

Today, Novo Nordisk A/S ( NVO ) has launched a pill version of Wegovy in the U.S., the news that many investors were waiting for. They’re now offering a 30-day supply at just $149 forI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind ...